ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
파머징(Pharmerging) 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 2조 422억 3,000만 달러로 평가되었고, 2025년에는 2조 2,592억 달러에 달하고, CAGR 10.6%로 성장할 전망입니다. 실적기간의 성장은 건강관리 지출 증가, 만성질환 유병률 증가, 중간층 확대, 도시화 진전, 건강과 웰빙에 대한 의식 증가로 인한 것으로 예측됩니다.
파머징(Pharmerging) 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 3조 3,391억 9,000만 달러로 성장하고, CAGR은 10.3%를 나타낼 전망입니다. 예측기간의 성장은 특수의약품에 대한 수요가 증가하고, 정부에 의한 헬스케어·이니셔티브의 확대, 헬스케어에 대한 의식과 리터러시의 향상, 의약품에 있어서의 E-Commerce의 침투 등이 요인으로 들 수 있습니다. 예측 기간의 주요 동향으로는 맞춤형 의료 솔루션 개발, 디지털 건강 플랫폼 통합, 약물전달 시스템 혁신, 의료 재정 모델 진보, 공급망 기술 도입 등이 있습니다.
헬스케어 지출 증가는 파머징(Pharmerging) 시장의 확대에 기여하고 있습니다. 헬스케어 지출이란 의료 서비스, 치료, 의료시설, 연구 및 건강 성과의 유지·향상을 목적으로 하는 공중 보건 프로그램에 대한 전체적인 재정 투자를 말합니다. 이 지출 증가는 더 빈번한 진단, 치료 및 장기 간호 서비스가 필요한 노화가 주요 요인입니다. 의료비 증가는 건강 관리 접근성을 개선하고, 인프라 확장을 가능하게 하고, 비용 효율적인 의약품의 광범위한 이용을 촉진함으로써 파머징(Pharmerging) 시장의 개척을 지원합니다. 예를 들어, 2024년 12월 미국 연방 정부 기관인 Medicare & Medicaid Service Center는 2023년 국민 의료비가 7.5% 증가한 4조 9,000억 달러에 이르렀고, 국내총생산의 17.6%를 차지했다고 보고했습니다. 게다가 2023년부터 2032년에 걸쳐 국민의료비는 연평균 5.6%의 속도로 성장했으며, 국내총생산에서 차지하는 의료비의 비율은 2022년의 17.3%에서 2032년에는 19.7%로 상승할 것으로 예측되고 있습니다. 이러한 헬스케어 지출 증가 동향이 파머징(Pharmerging) 시장의 성장을 뒷받침하고 있습니다.
파머징(Pharmerging) 시장의 기업은 복잡한 질병을 관리하고 환자의 결과를 개선하기 위해 약물 병용 요법과 같은 고급 치료의 개척에 주력하고 있습니다. 병용 요법은 치료 효과를 높이고 질병의 여러 측면을 동시에 표적화하기 위해 하나의 치료 계획에서 둘 이상의 효과적인 약제 성분을 사용하는 것입니다. 예를 들어 2024년 6월 인도에 본사를 둔 개발·제조 위탁회사인 아크무스 드럭스 앤 퍼머슈티칼스 리미티드는 위식도 역류증 및 기타 위장질환의 치료제로 인도 의약 감독청에서 승인한 제제인 라베프라졸 레보설피리드 서방형 캡슐은 위산의 분비를 억제하는 라베프라졸과 위와 장의 움직임을 활발하게 해 산의 역류를 막는 레보설피리드를 배합한 것입니다. 이 두 가지 접근법은 위산의 억제와 위장 운동의 개선에 대응하고 효과적인 완화를 실현합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 파머징(Pharmerging) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 파머징(Pharmerging) 시장 : 성장률 분석
세계의 파머징(Pharmerging) 시장 실적 : 규모와 성장, 2019년-2024년
세계의 파머징(Pharmerging) 시장 예측 : 규모와 성장, 2024년-2029년, 2034년
세계의 파머징(Pharmerging) : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 파머징(Pharmerging) 시장 : 제품 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
의약품
의료기기
진단
생명공학
제네릭 의약품
세계의 파머징(Pharmerging) 시장 : 적응증별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
생활습관병
암 및 자가면역 질환
감염증
기타 적응증
세계의 파머징(Pharmerging) 시장 : 제제별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
고형 경구제
액체 경구제
주사제
외용약
기타 제형 유형
세계의 파머징(Pharmerging) 시장 : 용도별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
치료
진단
예방
연구개발
세계의 파머징(Pharmerging) 시장 : 유통 채널별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
병원 및 클리닉
소매 약국
온라인 마켓플레이스
도매 판매자
소비자 직접 판매
세계의 파머징(Pharmerging) 시장 : 세분화 의약품, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
저분자 의약품
바이오 의약품
시판약
특허 의약품
브랜드 제네릭
백신
세계의 파머징(Pharmerging) 시장 : 세분화 의료기기, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
화상 진단 기기
외과용기구
환자 모니터링 장비
치료기기
이식가능 디바이스
세계의 파머징(Pharmerging) 시장 : 세분화 진단, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
체외 진단
분자 진단
화상 진단
포인트 오브 케어 검사
동반 진단
디지털 진단
세계의 파머징(Pharmerging) 시장 : 세분화 바이오 테크놀로지, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
유전체 의료
세포요법
유전자 치료
단일클론항체
바이오시밀러
세계의 파머징(Pharmerging) 시장 : 세분화 제네릭 의약품, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
경구 고형제 제네릭 의약품
주사용 제네릭 의약품
국소용 제네릭 의약품
흡입 가능 제네릭 의약품
안과용 제네릭 의약품
경피 흡수형 제네릭 의약품
제7장 지역별/국가별 분석
세계의 파머징(Pharmerging) 시장 : 지역별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
세계의 파머징(Pharmerging) 시장 : 국가별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
파머징(Pharmerging) 시장 : 경쟁 구도
파머징(Pharmerging) 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca PLC
Novartis AG
GlaxoSmithKline plc
Eli Lilly and Company
GE Healthcare Technologies Inc.
Alembic Ltd.
Intas Pharmaceuticals Ltd.
Sun Pharmaceutical Industries Limited
Aurobindo Pharma Limited
Dr. Reddy's Laboratories Ltd.
Cipla Limited
Aspen Pharmacare Holdings Limited
Zydus Lifesciences Limited
Lupin Limited
Beximco Pharmaceuticals Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
파머징(Pharmerging) 시장 2029년 : 새로운 기회를 제공하는 국가
파머징(Pharmerging) 시장 2029년 : 새로운 기회를 제공하는 부문
파머징(Pharmerging) 시장 2029년 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Pharmerging describes the strategy of pharmaceutical companies expanding into emerging markets to achieve growth and reach new patient populations. It emphasizes capturing opportunities in countries with rapidly developing healthcare systems and rising demand for medicines.
The primary product types in pharmerging are pharmaceuticals, medical devices, diagnostics, biotechnology, and generics. Pharmaceuticals are substances or products used for diagnosing, treating, preventing, or managing diseases and medical conditions. They are applied for various indications such as lifestyle diseases, cancer, autoimmune disorders, infectious diseases, and others, and are available in multiple formulations including solid oral, liquid oral, injectable, topical, and others. Their applications span therapeutic, diagnostic, preventive, and research and development areas, and they are distributed through hospitals and clinics, retail pharmacies, online marketplaces, wholesale distributors, and direct-to-consumer channels.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The pharmerging market research report is one of a series of new reports from The Business Research Company that provides pharmerging market statistics, including pharmerging industry global market size, regional shares, competitors with a pharmerging market share, detailed pharmerging market segments, market trends and opportunities, and any further data you may need to thrive in the pharmerging industry. This emerging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharmerging market size has grown rapidly in recent years. It will grow from $2042.23 billion in 2024 to $2259.20 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to higher healthcare expenditure, increasing prevalence of chronic diseases, expansion of the middle-class population, growing urbanization, and greater awareness of health and wellness.
The pharmerging market size is expected to see rapid growth in the next few years. It will grow to $3339.19 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to rising demand for specialty medicines, expanding government healthcare initiatives, increasing healthcare awareness and literacy, and greater penetration of e-commerce in pharmaceuticals. Key trends in the forecast period include development of personalized medicine solutions, integration of digital health platforms, innovations in drug delivery systems, advancements in health financing models, and incorporation of supply chain technologies.
Rising healthcare spending is contributing to the expansion of the pharmerging market. Healthcare expenditure refers to the overall financial investment in medical services, treatments, healthcare facilities, research, and public health programs aimed at maintaining or enhancing health outcomes. This rise in spending is largely driven by an aging population that requires more frequent medical attention, treatments, and long-term care services. Increased healthcare expenditure supports the development of the pharmerging market by improving access to healthcare, enabling the expansion of infrastructure, and promoting the broader availability of cost-effective medications. For example, in December 2024, the Centers for Medicare & Medicaid Services, a US federal agency, reported that national health expenditures grew by 7.5 percent to reach $4.9 trillion in 2023, accounting for 17.6 percent of the gross domestic product. Furthermore, from 2023 to 2032, national health expenditures are projected to grow at an average annual rate of 5.6 percent, with the share of health spending in the gross domestic product expected to rise from 17.3 percent in 2022 to 19.7 percent in 2032. This upward trend in healthcare spending is fueling the growth of the pharmerging market.
Companies in the pharmerging market are focusing on the development of advanced treatments such as combination drug therapies to manage complex diseases and improve patient outcomes. Combination therapies involve the use of two or more active pharmaceutical ingredients within a single treatment plan to enhance therapeutic effects and target multiple aspects of a disorder simultaneously. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based contract development and manufacturing company, introduced Rabeprazole and Levosulpiride sustained-release capsules, a formulation approved by the Drug Controller General of India for the treatment of gastroesophageal reflux disease and other gastrointestinal disorders. The capsules combine Rabeprazole, which reduces stomach acid production, with Levosulpiride, which enhances stomach and intestinal movement to prevent acid reflux. This dual approach provides effective relief by addressing both acid suppression and improved gastrointestinal motility.
In November 2022, Biocon Limited, a biopharmaceutical company based in India, acquired the global biosimilars business of Viatris Inc. for an undisclosed amount. Through this acquisition, Biocon aims to reinforce its global standing in the biosimilars segment by expanding its presence, increasing access to affordable therapies, and accelerating growth through product launches and a broader international footprint. Viatris Inc. is a US-based pharmaceutical company focused on delivering affordable medication solutions in pharmerging regions.
Major players in the pharmerging market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, GE Healthcare Technologies Inc., Alembic Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Limited, Lupin Limited, and Beximco Pharmaceuticals Ltd.
North America was the largest region in the pharmerging market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharmerging report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pharmerging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharmerging market consists of revenues earned by entities by providing services such as contract research and manufacturing services (CRAMS), diagnostic testing and healthcare services, distribution and retail pharmacy operations, and the supply of medical devices and equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmerging market also includes sales of over-the-counter (OTC) medicines, vaccines, biologics and biosimilars, and personal care and wellness products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharmerging Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pharmerging market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pharmerging ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmerging market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Pharmaceuticals; Medical Devices; Diagnostics; Biotechnology; Generics
2) By Indication: Lifestyle Diseases; Cancer And Autoimmune Diseases; Infectious Diseases; Other Indications
3) By Formulation: Solid Oral; Liquid Oral; Injectable; Topical; Other Formulation Types
4) By Application: Therapeutic; Diagnostic; Preventive; Research And Development
5) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Online Marketplaces; Wholesale Distributors; Direct-To-Consumer
Subsegments:
1) By Pharmaceuticals: Small Molecule Drugs; Biological Drugs; Over The Counter Drugs; Patented Drugs; Branded Generics; Vaccines
2) By Medical Devices: Diagnostic Imaging Devices; Surgical Instruments; Patient Monitoring Devices; Therapeutic Devices; Implantable Devices
3) By Diagnostics: In Vitro Diagnostics; Molecular Diagnostics; Imaging Diagnostics; Point Of Care Testing; Companion Diagnostics; Digital Diagnostics
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Pharmerging Market Characteristics
3. Pharmerging Market Trends And Strategies
4. Pharmerging Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Pharmerging Growth Analysis And Strategic Analysis Framework
5.1. Global Pharmerging PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Pharmerging Market Growth Rate Analysis
5.4. Global Pharmerging Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Pharmerging Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Pharmerging Total Addressable Market (TAM)
6. Pharmerging Market Segmentation
6.1. Global Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceuticals
Medical Devices
Diagnostics
Biotechnology
Generics
6.2. Global Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lifestyle Diseases
Cancer And Autoimmune Diseases
Infectious Diseases
Other Indications
6.3. Global Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solid Oral
Liquid Oral
Injectable
Topical
Other Formulation Types
6.4. Global Pharmerging Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic
Diagnostic
Preventive
Research And Development
6.5. Global Pharmerging Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Retail Pharmacies
Online Marketplaces
Wholesale Distributors
Direct-To-Consumer
6.6. Global Pharmerging Market, Sub-Segmentation Of Pharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Drugs
Biological Drugs
Over The Counter Drugs
Patented Drugs
Branded Generics
Vaccines
6.7. Global Pharmerging Market, Sub-Segmentation Of Medical Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Imaging Devices
Surgical Instruments
Patient Monitoring Devices
Therapeutic Devices
Implantable Devices
6.8. Global Pharmerging Market, Sub-Segmentation Of Diagnostics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
In Vitro Diagnostics
Molecular Diagnostics
Imaging Diagnostics
Point Of Care Testing
Companion Diagnostics
Digital Diagnostics
6.9. Global Pharmerging Market, Sub-Segmentation Of Biotechnology, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genomic Medicine
Cell Therapy
Gene Therapy
Monoclonal Antibodies
Biosimilars
6.10. Global Pharmerging Market, Sub-Segmentation Of Generics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Solid Dosage Generics
Injectable Generics
Topical Generics
Inhalable Generics
Ophthalmic Generics
Transdermal Generics
7. Pharmerging Market Regional And Country Analysis
7.1. Global Pharmerging Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Pharmerging Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Pharmerging Market
8.1. Asia-Pacific Pharmerging Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Pharmerging Market
9.1. China Pharmerging Market Overview
9.2. China Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Pharmerging Market
10.1. India Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Pharmerging Market
11.1. Japan Pharmerging Market Overview
11.2. Japan Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Pharmerging Market
12.1. Australia Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Pharmerging Market
13.1. Indonesia Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Pharmerging Market
14.1. South Korea Pharmerging Market Overview
14.2. South Korea Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Pharmerging Market
15.1. Western Europe Pharmerging Market Overview
15.2. Western Europe Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Pharmerging Market
16.1. UK Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Pharmerging Market
17.1. Germany Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Pharmerging Market
18.1. France Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Pharmerging Market
19.1. Italy Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Pharmerging Market
20.1. Spain Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Pharmerging Market
21.1. Eastern Europe Pharmerging Market Overview
21.2. Eastern Europe Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Pharmerging Market
22.1. Russia Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Pharmerging Market
23.1. North America Pharmerging Market Overview
23.2. North America Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Pharmerging Market
24.1. USA Pharmerging Market Overview
24.2. USA Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Pharmerging Market
25.1. Canada Pharmerging Market Overview
25.2. Canada Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Pharmerging Market
26.1. South America Pharmerging Market Overview
26.2. South America Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Pharmerging Market
27.1. Brazil Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Pharmerging Market
28.1. Middle East Pharmerging Market Overview
28.2. Middle East Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Pharmerging Market
29.1. Africa Pharmerging Market Overview
29.2. Africa Pharmerging Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Pharmerging Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Pharmerging Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Pharmerging Market Competitive Landscape And Company Profiles
30.1. Pharmerging Market Competitive Landscape
30.2. Pharmerging Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
31. Pharmerging Market Other Major And Innovative Companies
31.1. AstraZeneca PLC
31.2. Novartis AG
31.3. GlaxoSmithKline plc
31.4. Eli Lilly and Company
31.5. GE Healthcare Technologies Inc.
31.6. Alembic Ltd.
31.7. Intas Pharmaceuticals Ltd.
31.8. Sun Pharmaceutical Industries Limited
31.9. Aurobindo Pharma Limited
31.10. Dr. Reddy's Laboratories Ltd.
31.11. Cipla Limited
31.12. Aspen Pharmacare Holdings Limited
31.13. Zydus Lifesciences Limited
31.14. Lupin Limited
31.15. Beximco Pharmaceuticals Ltd.
32. Global Pharmerging Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Pharmerging Market
34. Recent Developments In The Pharmerging Market
35. Pharmerging Market High Potential Countries, Segments and Strategies
35.1 Pharmerging Market In 2029 - Countries Offering Most New Opportunities
35.2 Pharmerging Market In 2029 - Segments Offering Most New Opportunities
35.3 Pharmerging Market In 2029 - Growth Strategies
